tiprankstipranks
Upstream Bio, Inc. (UPB)
NASDAQ:UPB
US Market
UPB
Upstream Bio, Inc.
RESEARCH TOOLSreports
Want to see UPB full AI Analyst Report?

Upstream Bio, Inc. (UPB) Stock News & Sentiment

262 Followers
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
Premium
Market News
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
21d ago
UPB
AIOT
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
Premium
Ratings
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
23d ago
UPB
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
Premium
Company Announcements
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
1M ago
UPB
Upstream Bio Launches $150 Million At-The-Market Program
Premium
Company Announcements
Upstream Bio Launches $150 Million At-The-Market Program
1M ago
8K
UPB
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors
Premium
Ratings
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors
1M ago
UPB
Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster
Premium
Ratings
Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster
1M ago
UPB
Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug
Premium
Ratings
Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug
1M ago
UPB
More UPB News >

UPB News on the Web

Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
TipRanks News
Bullish
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
TipRanks News
Neutral
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and Pfizer (PFE)
TipRanks News
Bullish
Piper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)
TipRanks News
Bearish
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
TipRanks News
Bullish
Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
TipRanks News
Bearish
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
TipRanks News
Bearish

News Score - Last 7 Days

Neutral
UPB
Sector Average
Media Buzz
This Week1 articles
Weekly Average3.25 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is UPB’s Media Buzz Sentiment?
1 articles about UPB were published this week. In an average week, 3.25 articles are published.
    What is UPB’s weekly average amount of articles?
    In an average week, 3.25 articles about UPB are published.
      What is UPB’s News Sentiment?
      100% of articles about UPB were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week